Compare Aecom (ACM) vs InMode Ltd (INMD) Price & Performance

ACM's stock declined 16.73% to $61.04 amid a Q2 2026 earnings miss, reporting a loss of $0.50 per share versus expectations of $1.46. Despite the recent setback, the company maintains strong analyst support with a 64% buy rating and $88.25 consensus price target. Technical indicators show bearish momentum with the stock trading near key support levels, while fundamentals reveal mixed performance with positive revenue growth but negative ROE and ROA metrics.

The outlook remains cautiously optimistic given the significant analyst upside potential, though investors face near-term volatility from project execution challenges and ongoing securities investigation. Long-term infrastructure demand provides growth tailwinds, but recent earnings volatility and negative profitability ratios warrant careful monitoring of operational improvements.

INMD trades at $15.23, up 0.26% today, with a neutral technical outlook and mixed earnings history including a Q1 2026 miss. The company reported Q2 2026 revenue of $95.6 million, consistent year-over-year, and maintains a strong gross profit margin of 76.52%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and shareholder activism urging rejection, creating uncertainty around corporate governance.

The stock presents a value opportunity with low P/E and EV/EBITDA ratios, but risks include earnings volatility, potential acquisition fallout, and ongoing securities fraud investigations. Analyst consensus is divided between Buy and Hold ratings, reflecting cautious optimism amid near-term headwinds. Long-term growth depends on execution of international expansion and innovation in medical technologies.